Seth Lederman - 05 Feb 2025 Form 4 Insider Report for Tonix Pharmaceuticals Holding Corp. (TNXP)

Role
Chief Executive Officer, Director
Signature
/s/ Seth Lederman
Issuer symbol
TNXP
Transactions as of
05 Feb 2025
Net transactions value
-$18.38
Form type
4
Filing time
27 Feb 2025, 18:48:07 UTC
Previous filing
06 Mar 2024
Next filing
15 May 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TNXP Common Stock, $0.001 par value Other $17.51 -5 -51% $3.38 5 05 Feb 2025 Direct F2
transaction TNXP Common Stock, $0.001 par value Other $0.726 -0 -18% $3.30 1 05 Feb 2025 By IRA Account F2
transaction TNXP Common Stock, $0.001 par value Other $0.15 -1 -100% $0.1500 0 05 Feb 2025 By Spouse F2
holding TNXP Common Stock, $0.001 par value 5 05 Feb 2025 Direct
holding TNXP Common Stock, $0.001 par value 1 05 Feb 2025 By IRA Account
holding TNXP Common Stock, $0.001 par value 1 05 Feb 2025 Lederman & Co. F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TNXP Stock Option Award $0 +123,958 $0.000000 123,958 25 Feb 2025 Common Stock 123,958 $8.05 Direct F3, F4
transaction TNXP Stock Option Award $0 +123,958 $0.000000 123,958 25 Feb 2025 Common Stock 123,958 $10.06 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reporting person may be deemed to be a control person of this entity.
F2 Involuntary sale of fractional share following a reverse stock split of the Issuer's common stock.
F3 One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months.
F4 The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan.